Zydus receives EIR for the API manufacturing facility at Ankleshwar and Dabhasa
Zydus receives EIR for the API manufacturing facility at Ankleshwar
Zydus receives EIR for the API manufacturing facility at Ankleshwar
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
The 16,000-square-foot expansion enhances DuPont’s global sterile operations
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
Subscribe To Our Newsletter & Stay Updated